HERON THERAPEUTICS, INC. /DE/ — Director's Dealing 2021

May 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK: 0000818033
Period of Report: 2021-05-03

Reporting Person: MANHARD KIMBERLY (Director, EVP, Drug Development)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-04-30	Common Stock	J	1529	$13.8975	Acquired	3163	Direct
2021-05-03	Common Stock	S	1529	$17.6643	Disposed	1634	Direct

Footnotes

F1: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2021.

F2: The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of September 15, 2020.

F3: The range of sales prices received was $17.46 to $17.84. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.